Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DOCETAXEL Cause Hormone-refractory prostate cancer? 123 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 123 reports of Hormone-refractory prostate cancer have been filed in association with DOCETAXEL (Docetaxel). This represents 0.2% of all adverse event reports for DOCETAXEL.

123
Reports of Hormone-refractory prostate cancer with DOCETAXEL
0.2%
of all DOCETAXEL reports
4
Deaths
5
Hospitalizations

How Dangerous Is Hormone-refractory prostate cancer From DOCETAXEL?

Of the 123 reports, 4 (3.3%) resulted in death, 5 (4.1%) required hospitalization.

Is Hormone-refractory prostate cancer Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DOCETAXEL. However, 123 reports have been filed with the FAERS database.

What Other Side Effects Does DOCETAXEL Cause?

Alopecia (29,347) Emotional distress (8,373) Anxiety (7,379) Psychological trauma (6,981) Madarosis (6,883) Hair texture abnormal (6,204) Hair colour changes (6,078) Hair disorder (5,652) Pain (5,414) Diarrhoea (4,115)

What Other Drugs Cause Hormone-refractory prostate cancer?

RADIUM RA-223 DICHLORIDE (441) LEUPROLIDE (180) ENZALUTAMIDE (120) LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (110) DAROLUTAMIDE (104) ABIRATERONE (83) PREDNISONE (58) CABAZITAXEL (57) BICALUTAMIDE (50) CARBOPLATIN (27)

Which DOCETAXEL Alternatives Have Lower Hormone-refractory prostate cancer Risk?

DOCETAXEL vs DOCETAXEL ANHYDROUS DOCETAXEL vs DOCETAXEL\DOCETAXEL ANHYDROUS DOCETAXEL vs DOCONEXENT DOCETAXEL vs DOCONEXENT\ICOSAPENT DOCETAXEL vs DOCONEXENT\ICOSAPENT\PHOSPHATIDYL SERINE

Related Pages

DOCETAXEL Full Profile All Hormone-refractory prostate cancer Reports All Drugs Causing Hormone-refractory prostate cancer DOCETAXEL Demographics